Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05859412
Other study ID # 313200
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 17, 2023
Est. completion date April 1, 2026

Study information

Verified date January 2024
Source University of Oxford
Contact Annina Schmid, PhD
Phone +44 (0) 1865 223254
Email annina.schmid@ndcn.ox.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

INTRODUCTION: Carpal tunnel syndrome (CTS) is a relatively common condition caused by compression of one of the main nerves at the wrist, the median nerve. Non-surgical treatments, like steroid injections and physiotherapy, are the first line of treatment for patients with carpal tunnel syndrome. The investigators have previously shown that specific physiotherapeutic exercises (neurodynamic exercises) can reduce the need for carpal tunnel surgery in some patients. Experimental studies in animal models demonstrate that these exercises have an anti-inflammatory effect and can help the nerve to regenerate. However, the exact mechanisms of action of these exercises are not well understood in patients. A better understanding of the mechanisms of action of physiotherapeutic exercises would help clinicians to better target these treatments to those patients who may benefit from them. AIM: To investigate the mechanisms of action of 6 weeks' neurodynamic treatments on nerve function and structure as well as patient-reported outcome measures in patients with CTS compared to a positive control intervention (routine care steroid injection) and a negative control intervention (advice). METHODS AND ANALYSIS: In this single-blind randomised mechanistic trial, patients with confirmed mild to moderate CTS (n=78) and age and gender-matched healthy controls (n=30) will be included. Patients will be randomly allocated to a 6-week neurodynamic exercise group, steroid injection, or advice group. Outcome measures will be explored at baseline (patients and controls), post-intervention (patients), and 6-month follow-up (patients). Outcomes include diffusion-weighted and anatomical MRI of the median nerve at the wrist, quantitative sensory testing, nerve conduction studies, inflammatory markers in blood and skin biopsies, and validated questionnaires for pain, function, and psychological factors. Two-way repeated measures ANCOVAs (factors time and intervention, adjusted for baseline measurements as a continuous covariate) will be performed to identify differences in MRI parameters, clinical assessment, and inflammatory markers between patients in different groups and healthy controls.


Description:

Follow-up at 6 months will only include outcome measures from questionnaires. Details on enrollment: Pilot testing of healthy participants who consented to our ethics but will not be included in the study was on 13-April-2023. - First healthy participant enrolled: 17-May-2023. - First patient participant enrolled: 1-June-2023. Details on amendment: - Amendment SA2_BPOR on 3/Aug/2023 to expand recruitment through registries of patients - Amendment SA3_REC on 22/Aug/2023 to add Thames Valley Primary Care Research Partnership, musculoskeletal clinics, and media advertisement to help with recruitment of participants.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date April 1, 2026
Est. primary completion date February 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria Patients: 1. Patients who have a diagnosis of mild to moderate carpal tunnel syndrome based on a clinical assessment and confirmed with nerve conduction studies. 2. Male or Female, aged 18 years or above. 3. Patient is willing and able to give informed consent for participation in the study. Healthy participants: 1. Male or female aged 18 years or above. 2. Participant is willing and able to give informed consent for participation in the study. 3. No history of hand or arm symptoms 4. No history of neck pain in the past 3 months 5. No systemic medical condition 6. No strong anticoagulant medication or altered coagulation (e.g., hemophilia) preventing skin biopsies 7. Severe anxiety or depression 8. Participants are required to be age- & sex-matched to patient participants 9. No contraindications for magnetic resonance scanning at 3T 10. Sufficient command of the English language Exclusion Criteria Patients: 1. Patients who already had surgery for their carpal tunnel syndrome (CTS) or are planning to undergo surgery in the next 6 weeks (patients with unilateral surgery who have unoperated CTS on the other hand are eligible to participate) 2. Patients who had a steroid injection for their CTS in the 6 months prior to the study enrolment or who had already more than 1 steroid injection into the study wrist. 3. Patients who have a diagnosis of severe carpal tunnel syndrome based on a clinical assessment and confirmed with electrodiagnostic testing 4. Electrodiagnostic testing revealing abnormalities other than CTS 5. Any other upper limb or neck problem for which they have sought treatment in the past 3 months 6. History of significant trauma to the upper limb or neck 7. Diabetes 8. Hypothyroidism 9. Severe anxiety or depression 10. Patient who is pregnant, lactating, or planning pregnancy during the study. 11. Patients on strong anticoagulant medication or altered coagulation preventing skin biopsies. 12. Contraindications for magnetic resonance imaging (assessed with MRI safety screening questionnaire). 13. Contraindications for steroid injections 14. Insufficient command of the English language

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Neurodynamic exercises
The neurodynamic exercises will consist of a home-based exercise programme performed over a period of 6 weeks. Patients will attend a single session with an investigator who will instruct them the home exercise programme consisting of nerve and tendon gliding exercises which will be adjusted with pre-specified progressions over the 6 weeks intervention period. Patients will receive a leaflet and a video link detailing these exercises.
Drug:
Steroid injection (Depomedrone 40mg)
Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
Other:
Advice
Group receiving advice but no additional treatment

Locations

Country Name City State
United Kingdom Nuffield Department of Clinical Neurosciences, University of Oxford Oxford Oxfordshire

Sponsors (2)

Lead Sponsor Collaborator
University of Oxford Wellcome Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Blood samples - DNA Blood samples coupled with detailed phenotype data will investigate potential gene associations in CTS and recovery Baseline
Other Change in blood samples - DNA Change in blood samples coupled with detailed phenotype data will investigate potential gene associations in CTS and recovery From baseline to post-intervention (after 6-weeks)
Other Concentration of serum inflammatory markers - metabolomics Concentrations of inflammatory markers in serum Baseline
Other Change in the concentration of serum inflammatory markers - metabolomics Change in the concentrations of inflammatory markers in serum From baseline to post-intervention (after 6-weeks)
Other Pro-inflammatory cytokine levels Proinflammatory cytokine assay (pg/ml); continuous data Baseline
Other Change in pro-inflammatory cytokine levels Change in proinflammatory cytokine assay (pg/ml); continuous data From baseline to post-intervention (after 6-weeks)
Other Concentration of inflammatory markers in serial skin biopsies Concentration of inflammatory markers in skin biopsies. Baseline biopsy will be performed in the most distal part of the ventrolateral side of the proximal phalanx of the index finger. The 6-weeks biopsy will be performed proximally, avoiding the primary biopsy site Baseline
Other Change in concentration of inflammatory markers in serial skin biopsies Change in concentration of inflammatory markers in skin biopsies. Baseline biopsy will be performed in the most distal part of the ventrolateral side of the proximal phalanx of the index finger. The 6-weeks biopsy will be performed proximally, avoiding the primary biopsy site From baseline to post-intervention (after 6-weeks)
Primary Median nerve fractional anisotropy as determined on diffusion weighted imaging Fractional anisotropy will be extracted from regions-of-interest in the median nerve and compared to healthy control group Baseline
Primary Change in median nerve fractional anisotropy as determined on diffusion weighted imaging Change in fractional anisotropy extracted from regions-of-interest in the median nerve at post-intervention (after 6-weeks) compared to baseline From baseline to post-intervention (after 6-weeks)
Secondary Nerve markers on diffusion weighted imaging: water diffusivity (mm2/s) Measured at the median nerve and cervical dorsal root ganglia. mm2/s; continuous data Baseline
Secondary Change to nerve markers on diffusion weighted imaging: water diffusivity (mm2/s) Measured at the median nerve and cervical dorsal root ganglia. mm2/s; continuous data From baseline to post-intervention (after 6-weeks)
Secondary Nerve markers on anatomical MRI Measured at the median nerve and cervical dorsal root ganglia. ratio/mm2; continuous data Baseline
Secondary Change in nerve markers on anatomical MRI Measured at the median nerve and cervical dorsal root ganglia. ratio/mm2; continuous data From baseline to post-intervention (after 6-weeks)
Secondary Median nerve MRI T2 mapping ms; continuous data Baseline
Secondary Changes in median nerve MRI T2 mapping ms; continuous data From baseline to post-intervention (after 6-weeks)
Secondary Median nerve MRI magnetisation transfer ratio (MTR) ratio; continuous data Baseline
Secondary Changes in median nerve MRI magnetisation transfer ratio (MTR) ratio; continuous data From baseline to post-intervention (after 6-weeks)
Secondary Changes in median nerve conduction velocities from electrodiagnostic studies (m/s) m/s; continuous data From baseline to post-intervention (after 6-weeks)
Secondary Changes in median sensory nerve action potentials (SNAPs) and compound muscle action potentials (CMAPs): amplitudes (mV) mV; continuous data From baseline to post-intervention (after 6-weeks)
Secondary Thermal detection thresholds as assessed in Quantitative Sensory testing - warm and cold detection threshold; thermal sensory limen Thermal detection thresholds will be assessed using a thermode over the index finger (e.g., ventral aspect of the proximal phalanx of the index finger).
Data is measured in degrees celsius (point at which cold or warm is detected)
Baseline
Secondary Change in thermal detection thresholds as assessed in Quantitative Sensory testing- warm and cold detection threshold; thermal sensory limen Thermal detection thresholds will be assessed using a thermode over the index finger (e.g., ventral aspect of the proximal phalanx of the index finger).
Data is measured in degrees celsius (point at which cold or warm is detected)
From baseline to post-intervention (after 6-weeks)
Secondary Thermal pain thresholds as assessed in Quantitative Sensory testing- warm and cold painful threshold Pain thermal thresholds will be assessed using a thermode over the index finger (e.g., ventral aspect of the proximal phalanx of the index finger) and over the contralateral lower limb (tibial anterior).
Data is measured in degrees celsius (point at which cold or warm is initially detected as painful)
Baseline
Secondary Change in thermal pain thresholds as assessed in Quantitative Sensory testing- warm and cold painful threshold Pain thermal thresholds will be assessed using a thermode over the index finger (e.g., ventral aspect of the proximal phalanx of the index finger) and over the contralateral lower limb (tibial anterior).
Data is measured in degrees celsius (point at which cold or warm is initially detected as painful)
From baseline to post-intervention (after 6-weeks)
Secondary Mechanical detection thresholds as assessed in Quantitative sensory testing Mechanical detection thresholds will be assessed using a standardised set of von Frey filaments (mN) over the index finger. Geometric mean will be calculated Baseline
Secondary Change in mechanical detection thresholds as assessed in Quantitative sensory testing Mechanical detection thresholds will be assessed using a standardised set of von Frey filaments (mN) over the index finger. Geometric mean wil be calculated From baseline to post-intervention (after 6-weeks)
Secondary Mechanical pain thresholds as assessed in Quantitative sensory testing Mechanical pain thresholds will be assessed using a series of weighted pin prick stimulators (mN). They will be assessed over the index finger and over the contralateral lower limb (tibial anterior). Baseline
Secondary Change in mechanical pain thresholds as assessed in Quantitative sensory testing Mechanical pain thresholds will be assessed using a series of weighted pin prick stimulators (mN). They will be assessed over the index finger and over the contralateral lower limb (tibial anterior). From baseline to post-intervention (after 6-weeks)
Secondary Mechanical pain sensitivity as assessed in Quantitative sensory testing Mechanical pain sensitivity will be assessed using a series of weighted pin prick stimulators (mN) over the index finger. Pain rating for each stimulus on a 0-100 numerical rating scale ('0' indicating "no pain", and '100' indicating "most intense pain imaginable"). Geometric mean of all numerical ratings for pinprick stimuli will be calculated Baseline
Secondary Change in mechanical pain sensitivity as assessed in Quantitative sensory testing Mechanical pain sensitivity will be assessed using a series of weighted pin prick stimulators (mN) over the index finger. Pain rating for each stimulus on a 0-100 numerical rating scale ('0' indicating "no pain", and '100' indicating "most intense pain imaginable"). Geometric mean of all numerical ratings for pinprick stimuli will be calculated From baseline to post-intervention (after 6-weeks)
Secondary Dynamic mechanical allodynia as assessed in Quantitative sensory testing Pain rating for each stimulus on a 0-100 numerical rating scale ('0' indicating "no pain", and '100' indicating "most intense pain imaginable"). Geometric mean (compound measure) of all numerical ratings across light touch stimulators over the index finger Baseline
Secondary Change in dynamic mechanical allodynia as assessed in Quantitative sensory testing Pain rating for each stimulus on a 0-100 numerical rating scale ('0' indicating "no pain", and '100' indicating "most intense pain imaginable"). Geometric mean (compound measure) of all numerical ratings across light touch stimulators over the index finger From baseline to post-intervention (after 6-weeks)
Secondary Wind-up ratio as assessed in Quantitative sensory testing Wind-up ration will be assessed using a pin prick (mN) over the index finger (e.g., ventral aspect of the proximal phalanx of the index finger). Ratio, continous data Baseline
Secondary Change in wind-up ratio as assessed in Quantitative sensory testing Change in wind-up ration will be assessed using a pin prick (mN) over the index finger (e.g., ventral aspect of the proximal phalanx of the index finger). Ratio, continuous data From baseline to post-intervention (after 6-weeks)
Secondary Vibration detection thresholds as assessed in Quantitative sensory testing Vibration detection thresholds will be assessed using a tuning fork (64 Hz, 8/8 scale) over a bony prominence over (e.g., palmar side of the distal end of the second metacarpal) Baseline
Secondary Change in vibration detection thresholds as assessed in Quantitative sensory testing Change in vibration detection thresholds will be assessed using a tuning fork (64 Hz, 8/8 scale) over a bony prominence over (e.g., palmar side of the distal end of the second metacarpal) From baseline to post-intervention (after 6-weeks)
Secondary Pressure pain thresholds as assessed in Quantitative sensory testing Pressure pain thresholds will be assessed using an algometer (kg) on the thenar eminence and over the contralateral lower limb (tibialis anterior) Baseline
Secondary Change in pressure pain thresholds as assessed in Quantitative sensory testing Change in pressure pain thresholds will be assessed using an algometer (kg) on the thenar eminence and over the contralateral lower limb (tibialis anterior) From baseline to post-intervention (after 6-weeks)
Secondary Pinch strength test - maximum isometric strength Pinch grip dynamometry. Continuous data, kg Baseline
Secondary Change in pinch strength test - maximum isometric strength Pinch grip dynamometry. Continuous data, kg From baseline to post-intervention (after 6-weeks)
Secondary Nerve mechanosensitivity- upper limb neurodynamic test (median nerve) Evaluation of nerve mechanosensitivity in response to mechanical load (increased tension) applied to the nerve. Range of elbow extension at point of symptoms (degrees) Baseline
Secondary Change in nerve mechanosensitivity- upper limb neurodynamic test (median nerve) Change in nerve mechanosensitivity in response to mechanical load (increased tension) applied to the nerve. Range of elbow extension at point of symptoms (degrees) From baseline to post-intervention (after 6-weeks)
Secondary Nerve mechanosensitivity - positive upper limb neurodynamic tests Upper limb neurodynamic tests will be assessed to determine the presence of increased mechanosensitivity. The neurodynamic test will be graded as 'positive', when there is at least partial reproduction of symptoms plus when symptoms can be modified with structural differentiation. Otherwise, the neurodynamic test will be graded as 'negative' Baseline
Secondary Change in nerve mechanosensitivity - positive upper limb neurodynamic tests Upper limb neurodynamic tests will be assessed to determine the presence of increased mechanosensitivity. The neurodynamic test will be graded as 'positive', when there is at least partial reproduction of symptoms and when symptoms can be modified with structural differentiation. Otherwise, the neurodynamic test will be graded as 'negative' From baseline to post-intervention (after 6-weeks)
Secondary Symptom severity and limitations in hand function as assessed by the Boston carpal tunnel syndrome questionnaire Patient reported symptoms and limitations on the Boston carpal tunnel syndrome questionnaire Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Symptom intensity levels on a Visual Analogue Scale (VAS) Patient reported average intensity of pain, paraesthesia and numbness on 10cm visual analogue scales, ranging from no symptoms to worst symptoms ever Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Location of symptoms in a body and a hand diagram Patient reported location of symptoms in a body diagram and a hand diagram. Baseline, post-intervention (after 6 weeks)
Secondary Presence of central sensitisation as assessed with the Central Sensitisation Inventory Patient reported central sensitisation on the Central Sensitisation Inventory Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Functional deficits- Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire Participant reported outcomes on ability to perform activities as per quick DASH questionnaire Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Functional deficits- Patient specific functional scale (PSFS) Participant reported outcomes on the patient specific functional scale Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Presence of neuropathic pain - DN4 Patient screened for neuropathic pain using DN4 Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Presence of neuropathic pain - pain DETECT Patient screened for neuropathic pain using pain DETECT Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Neuropathic pain symptoms - Neuropathic Pain Symptom Inventory Patient reported outcomes on neuropathic pain symptoms as assessed on Neuropathic Pain Symptom Inventory. Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Presence of psychological co-morbidities - The Depression, Anxiety, and Positive Outlook Scale (DAPOS) Participant reported outcomes on depression and anxiety as per DAPOS Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Presence of psychological co-morbidities - short-form Pain Anxiety Symptoms Scale (PASS-20) Participant reported outcomes on depression and anxiety as per short-form Pain Anxiety Symptoms Scale (PASS-20) Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Presence of psychological co-morbidities - pain catastrophizing scale (PCS) Participant reported outcomes on depression and anxiety as per pain catastrophising scale (PCS) Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Assessment of quality of life - EQ-5D-5L Participant reported outcomes on quality of life as per EQ-5D-5L questionnaire Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Assessment of sleep interference - Insomnia Severity Index Participant reported outcomes on sleep interference with the Insomnia Severity Index. Baseline, post-intervention (after 6 weeks), 6-months follow up
Secondary Adverse and serious adverse events Patient self-reported adverse events From start of intervention until end of intervention (6 weeks)
Secondary Exercise adherence to the neurodynamic home-based intervention - number of sessions Patient self-reported number of sessions per day throughout the intervention in an exercise diary From start of intervention until end of intervention (6 weeks)
See also
  Status Clinical Trial Phase
Completed NCT05067205 - Minimal Invasive Carpal Tunnel Release With the Novel Device N/A
Completed NCT03184688 - Platelet Rich Plasma for Carpal Tunnel Syndrome N/A
Completed NCT03582735 - Preoperative Neuromobilization Exercises for Individuals With Carpal Tunnel Syndrome N/A
Completed NCT05490420 - Effects of Upper Extremity Manual Lymphatic Drainage on Symptom Severity, Hand Functions, Electrophysiological and Ultrasonographic Measurements in Carpal Tunnel Syndrome N/A
Recruiting NCT05970692 - Cross-Cultural Adaptation and Psychometric Validation of the Turkish Version of Atroshi-Lyrén 6-item Symptoms Scale
Completed NCT04043780 - Clinical Validation of a Decompression Prototype Splint for Patients With Carpal Tunel Syndrome N/A
Completed NCT03880812 - Cost Information on Carpal Tunnel Syndrome Treatment Decisions N/A
Completed NCT06464809 - Treatment Intervention of Patients With Carpal Tunnel Syndrome (CTS) N/A
Recruiting NCT05503719 - An Absorbable Suture Versus a Non-absorbable Suture in Carpal Tunnel Release, a Randomized Controlled Trial N/A
Recruiting NCT05372393 - Carpal Tunnel Release Under Local Anaesthesia With or Without Distal Median Nerve Block N/A
Recruiting NCT05328180 - aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE) N/A
Recruiting NCT05466162 - Soft Tissue Massage Along With Mobilization Technique on Symptoms and Functional Status of Carpal Tunnel Syndrome N/A
Completed NCT04060875 - Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain
Not yet recruiting NCT06294821 - 4AP to Delay Carpal Tunnel Release (CTR) Phase 2/Phase 3
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Terminated NCT02791529 - Scalpel Versus Electrocautery for Surgical Skin Incision in Open Carpal Tunnel Release Phase 1
Completed NCT02141035 - Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome Phase 2/Phase 3
Completed NCT01887145 - Comparison of Long-term Outcomes Following Endoscopic or Open Surgery for Carpal Tunnel Syndrome N/A
Recruiting NCT01897272 - Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective Study N/A
Completed NCT01394822 - Neuromuscular Ultrasound for Focal Neuropathies N/A